These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37366225)

  • 1. The highs and lows of serous ovarian cancer.
    Grisham RN; Manning-Geist BL; Chui MH
    Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BRAF pathway in low-grade serous ovarian cancer.
    Perrone C; Angioli R; Luvero D; Giannini A; Di Donato V; Cuccu I; Muzii L; Raspagliesi F; Bogani G
    J Gynecol Oncol; 2024 Jul; 35(4):e104. PubMed ID: 38768941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutics in low-grade serous ovarian cancer.
    Cobb L; Gershenson D
    Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
    Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
    Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
    Tholander B; Koliadi A; Botling J; Dahlstrand H; Von Heideman A; Ahlström H; Öberg K; Ullenhag GJ
    Ups J Med Sci; 2020 Nov; 125(4):325-329. PubMed ID: 33043759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic opportunities for women with low-grade serous ovarian cancer.
    Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
    Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
    Grisham RN; Iyer G
    Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular pathology of ovarian serous borderline tumors.
    Malpica A; Wong KK
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
    Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
    McLachlan J; Gore M; Banerjee S
    Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.